Healthcare / BiotechnologyParis
$0.22
-0.01 (-3.28%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-16.9M · quality 54.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$14M
P/E
N/A
•EV/EBITDA
N/A
•ROE
71.5%
↑Gross Margin
0.1%
↓Debt/Equity
-0.96
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2023 · 2 años de histórico normalizado
Revenue CAGR
-61.5%
FCF CAGR
—
FCF margin
-705.6%
FCF / Net income
0.40x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.0M · net income $-35.1M · FCF $-14.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $2.0M | $2.0M | $674000.00 | $13.4M |
| Net Income | $-35.1M | $-35.1M | $-31.4M | $-23.8M |
| EBITDA | $-12.2M | $-12.2M | $-27.0M | $-20.7M |
| EPS | -1.05 | -1.05 | -1.08 | -0.83 |
| Gross Margin | 0.1% | 0.1% | 0.3% | 99.6% |
| Operating Margin | -1451.9% | -1451.9% | -3247.8% | -167.7% |
| Net Margin | -1771.3% | -1771.3% | -4658.5% | -177.4% |
| Balance Sheet | ||||
| Debt/Equity | -0.96 | -0.96 | -2.38 | 4.28 |
| Current Ratio | 0.26 | 0.26 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $-14.0M | $-14.0M | $-21.8M | $-16.9M |
| Returns | ||||
| ROE | 71.5% | 71.5% | 172.1% | -289.6% |
| Valuation | ||||
| P/B | — | — | — | 16.76 |
| Growth & Yield | ||||
| Revenue Growth | 193.9% | 193.9% | -95.0% | — |
| EPS Growth | 2.8% | 2.8% | -30.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-66.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.08 → -1.05
Residual
-66.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.